Relevant bibliographies by topics / 200102 Efficacy of medications

Academic literature on the topic '200102 Efficacy of medications'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '200102 Efficacy of medications.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "200102 Efficacy of medications"

1

Park, Sea Mi, Halinder S. Mangat, Karen Berger, and Axel J. Rosengart. "Efficacy spectrum of antishivering medications." Critical Care Medicine 40, no. 11 (November 2012): 3070–82. http://dx.doi.org/10.1097/ccm.0b013e31825b931e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Feren, Stephen, Anup Katyal, and James K. Walsh. "Efficacy of Hypnotic Medications and Other Medications Used for Insomnia." Sleep Medicine Clinics 1, no. 3 (September 2006): 387–97. http://dx.doi.org/10.1016/j.jsmc.2006.06.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pappachan, Joseph M. "Efficacy and Cardiovascular Safety of Antidiabetic Medications." Current Drug Safety 16, no. 2 (June 8, 2021): 115–21. http://dx.doi.org/10.2174/1574886316666210112153429.

Full text
Abstract:
: Diabetes mellitus (DM) has already affected one in every eleven person in the global population, and the dis-ease prevalence continues to increase because of the obesity pandemic. Even with the availability of a multitude of antidi-abetic medications for optimal glycaemic control, cardiovascular morbidity and mortality were not largely altered until re-cently when newer antidiabetic drugs such as glucagon-like peptide-1 receptor analogues (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were introduced. Cardiovascular safety of antidiabetic drugs has also been a hot topic for global scientific debate after the US Food and Drug Administration (FDA) enforced restrictions on Rosiglita-zone in 2010 with the suspicion of increased mortality and myocardial events (with subsequent uplift of the ban on the drug in 2013 following the emergence of additional evidence on safety). After this debate, all antidiabetic should go through rigorous safety checks with cardiovascular outcome trials (CVOTs). Recent CVOTs with GLP-1RAs and SGLT2 inhibitors have revealed markedly positive outcomes that have changed the landscape of diabetes management across the world. Thus, the therapeutic algorithm for optimal management of DM should consider not only the glycaemic control ef-ficacy of the individual antidiabetic agent but also the cardiovascular safety and modifications in other anticipated long-term DM complication profiles. Therefore, it is imperative to critically appraise the efficacy and cardiovascular safety of all antidiabetic drugs to improve the scientific practice of our diabetes care globally. This issue, “Efficacy and cardiovas-cular safety of antidiabetic medications,” provides readers the back-up of up to date evidence.
APA, Harvard, Vancouver, ISO, and other styles
4

Ed, Susman. "Omalizumab enhances efficacy of established asthma medications." Inpharma Weekly &NA;, no. 1382 (April 2003): 7–8. http://dx.doi.org/10.2165/00128413-200313820-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sleath, Betsy, Susan J. Blalock, David Covert, Asheley Cockrell Skinner, Kelly W. Muir, and Alan L. Robin. "Patient Race, Reported Problems in Using Glaucoma Medications, and Adherence." ISRN Ophthalmology 2012 (November 21, 2012): 1–7. http://dx.doi.org/10.5402/2012/902819.

Full text
Abstract:
Objective. The objectives of the study were to (a) describe various factors potentially related to objectively measured adherence to glaucoma medications and self-reported glaucoma medication adherence self-efficacy and (b) examine the relationship between patient race, the number of patient reported-problems, and adherence in taking their glaucoma medication. This was a cross-sectional study conducted at two glaucoma subspecialist referral ophthalmology practices. Methods. We measured subjects' reported problems in using glaucoma medications, adherence to glaucoma medications utilizing the Medication Events Monitoring System (MEMS) devices, and general glaucoma medication adherence self-efficacy using a previously validated 10-item scale. Multivariable logistic and linear regression was used to analyze the data. Results. Seventy-one percent of patients self-reported at least one problem in using their glaucoma medications. White patients were more than 3 times more likely to be 80% adherent in using their glaucoma medications than non-White patients. Patients who had glaucoma longer reported significantly higher glaucoma medication adherence self-efficacy. Patients who reported more problems in using their medications had significantly lower glaucoma medication adherence self-efficacy. Conclusions. Eye care providers should assess patient reported problems and glaucoma medication adherence self-efficacy and work with patients to find ways to reduce the number of problems that patients experience to increase their self-efficacy in using glaucoma medications.
APA, Harvard, Vancouver, ISO, and other styles
6

Babic, Nikola. "Fixed combinations of glaucoma medications." Srpski arhiv za celokupno lekarstvo 143, no. 9-10 (2015): 626–31. http://dx.doi.org/10.2298/sarh1510626b.

Full text
Abstract:
The first line treatment in the management of glaucoma is topical medical therapy. Many patients with glaucoma require multiple medications for adequate intraocular pressure control. For patients who need multi-dose regimens to control intraocular pressure, fixed combinations offer convenience, efficacy and safety. This review summarizes the role, efficacy, mechanism of action and indications for use of modern fixed combination of topical glaucoma medications. The review shows the advantages and disadvantages of a prescribing fixed combination in daily clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
7

Kwon, Hyuk-Sang. "Mechanism and Efficacy of New Anti-diabetic Medications." Journal of Korean Diabetes 13, no. 4 (2012): 167. http://dx.doi.org/10.4093/jkd.2012.13.4.167.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Arya, Ravindra, Harsh Kothari, Zongjun Zhang, Baoguang Han, Paul S. Horn, and Tracy A. Glauser. "Efficacy of nonvenous medications for acute convulsive seizures." Neurology 85, no. 21 (October 28, 2015): 1859–68. http://dx.doi.org/10.1212/wnl.0000000000002142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

WACHTER, KERRI. "Think Efficacy and Toxicity in Selecting Psoriasis Medications." Family Practice News 38, no. 23 (December 2008): 23. http://dx.doi.org/10.1016/s0300-7073(08)71432-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Berman, James. "Limited efficacy of antigastroesophageal reflux medications in children." Journal of Pediatrics 166, no. 5 (May 2015): 1320–23. http://dx.doi.org/10.1016/j.jpeds.2015.02.061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "200102 Efficacy of medications"

1

Melius, Joyce. "Mathematics Anxiety and Mathematics Self-efficacy in Relation to Medication Calculation Performance in Nurses." Thesis, University of North Texas, 2012. https://digital.library.unt.edu/ark:/67531/metadc115119/.

Full text
Abstract:
The purpose of this study is to identify and analyze the relationships that exist between mathematics anxiety and nurse self-efficacy for mathematics, and the medication calculation performance of acute care nurses. This research used a quantitative correlational research design and involved a sample of 84 acute care nurses, LVNs and RNs, from a suburban private hospital. the participants filled out a Mathematics Anxiety Scale, a Nurse Self-Efficacy for Mathematics Scale and also completed a 20-item medication calculation test. Significant practical and statistical relationships were discovered between the variables utilizing multiple linear regression statistics and commonality analysis. As the Nurse’s Mathematics anxiety score increased the scores on the medication test decreased and the scores on nurse self-efficacy for mathematics scale also decreased. the demographic item of “Hours a nurse worked in one week” had the greatest significance. the more hours a nurse worked the lower their score was on the medication calculation test. This study agrees with others that nurses are not good at mathematics. This study also correlated that as the number of hours worked increased so did the medication calculations errors. and many nurses have a measurable level of anxiety about mathematics and dosage calculations and this may influence calculation ability. Suggestions for further research include refinement of instruments used in study, further differentiation of barriers to successful medication calculation performance, and testing of interventions used to teach, train and evaluate accurate medication administration in nurses.
APA, Harvard, Vancouver, ISO, and other styles
2

Sarwary, Mariam. "Comparison of cognitive decline medications of Alzheimer´s disease : Efficacy and safety of Donepezil, Galantamine, Rivastigmine and Memantine." Thesis, Umeå universitet, Farmakologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-136250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Velazquez, Raquel. "The efficacy of anti-psychotic medications in treating the behavior, social, and communication deficits associated with autism spectrum disorders in children and adolescents a systematic review." Honors in the Major Thesis, University of Central Florida, 2012. http://digital.library.ucf.edu/cdm/ref/collection/ETH/id/636.

Full text
Abstract:
Background: Autism spectrum disorders (ASD) are a group of complex developmental disabilities which can cause behavior, social, and communication deficits. Anti-psychotic medications are often prescribed when symptoms such as aggression, irritability, hyperactivity, tantrums, and self-injurious behavior occur. Objective: To determine if anti-psychotic medications improve the behavior, social, and communication symptoms associated with ASD in children and adolescents. Search Strategy: Electronic literature searches were performed to find relevant studies and utilized the (1) Cochrane Database of Systematic Reviews, (2) Hispanic American Periodicals Index, (3) Medline, (4) PAIS International, (5) ProQuest Dissertations and Theses, (6) PsycInfo, (7) PubMed, (8) Springer LINK, (9) Taylor and Francis Journals, and (10) Sage Premier. Selection Criteria: Randomized controlled trials (RCTs) or quasi-experimental design (QED) studies of any dose of an anti-psychotic medication compared to a placebo or other prescription drug, in participants with autism spectrum disorder. Data Collection and Analysis: All studies which met the full-text level criteria were reviewed by a third party to validate the decision of inclusion. Meta-analyses in this review implemented both random and fixed-effects models. Main Results: Ten RCTs were included. Six studies evaluated a drug versus a placebo and four studies investigated the effects of two separate anti-psychotic medications or the efficacy of an additive medication to a drug and placebo group. Author's Conclusions: Limited evidence suggests the effectiveness of anti-psychotic medications in treating the behavior, social, and associated with autism; however, further research is needed to determine the implications of long-term use.
B.A. and B.S.
Bachelors
Office of Undergraduate Studies
Interdisciplinary Studies
APA, Harvard, Vancouver, ISO, and other styles
4

Paterson, Ruth Elizabeth. "Development and evaluation of a theoretical model to predict medicines adherence in people with mild to moderate intellectual disability and diabetes : a mixed methods study." Thesis, Edinburgh Napier University, 2018. http://researchrepository.napier.ac.uk/Output/1526669.

Full text
Abstract:
Background: Fifty percent of medications are not taken as prescribed. This is a major public health issue yet there is very limited evidence on the factors associated with medicines adherence in people with mild to moderate Intellectually Disabilities and diabetes (IDD). This study evaluated the frequency of, and factors associated with, medicines non-adherence in this group compared to people without ID but with diabetes (non-IDD).Methods: A systematic review of the literature informed the theoretical model tested. A two-stage, sequential mixed methods study with 111 people with type 1 and 2 diabetes, (IDD = 33, non-IDD = 78) was then carried out. Stage one (quantitative) compared frequency of medication adherence in the group overall, IDD and non-IDD. Univariate and multiple regression analysis evaluated associations between factors (ID, depression, side effects, self-efficacy and perceived level of social support) and medicines non-adherence. Stage two (qualitative) explored findings of stage one with 12 stage one participants' carers using semi-structured interviews. Results: Data were collected between July 2014 and May 2016. The frequency of medicines adherence was similar in the IDD and non-IDD population (70% vs 62%, p = 0.41). The theoretical model did not predict medicines non-adherence. After controlling for support with medicines and complexity of regime (number of medications and use of insulin), depression was an independent predictor in the non-IDD and group overall (p < 0.001). In the IDD group, perceived side effects was an important, but non-significant, predictor of non-adherence (p = 0.06). Carers' perceptions of adherence and depression were consistent with stage one findings. Conclusions: Optimising adherence to diabetes medicines is equally challenging in IDD and non-IDD populations. Associations between independent factors and adherence differed between the two groups: in the non-IDD population, depressive symptoms were associated with non-adherence whereas in the IDD population perceived level of side effects appeared most dominant. Due to small sample sizes findings were inconclusive therefore, a sufficiently powered study further investigating the relationship between adherence and side effects in people with ID and diabetes is recommended.
APA, Harvard, Vancouver, ISO, and other styles
5

Adefolalu, Adegoke Olusegun. "Self-efficacy and beliefs about medications: implications for antiretroviral therapy adherence." Thesis, 2013. http://hdl.handle.net/10500/10571.

Full text
Abstract:
The earlier optimism generated by the efficacy of antiretroviral drugs in human immuno-deficiency virus (HIV) patients has been dissipated in the face of the enormous chal-lenge of maintaining a nearly perfect adherence indefinitely. This study set to determine the influence of HIV adherence self-efficacy and beliefs about medicines on antiretrovi-ral therapy adherence, with the aim of developing a framework for enhancing antiretrovi-ral therapy (ART) adherence through focused intervention on modifiable factors from study variables that are strongly associated with ART adherence. A descriptive correlational design was used to assess the predictive relationships of HIV adherence Self-Efficacy, Beliefs about Medicines and ART adherence among 232 HIV-infected patients in a large public health facility in Pretoria. Participants' medication be-liefs were assessed using the Beliefs about Medicines Questionnaire, HIV adherence self-efficacy was assessed with HIV adherence self-efficacy scale (HIV-ASES) and ART adherence was assessed using the AIDS Clinical Trial Group questionnaire. Pearson correlation analysis was used to assess bivariate associations among the variables, and multiple regression analysis was used to examine the relationships among the inde-pendent variables and ART adherence. Mean adherence for the 232 participants was 95% (SD=13.2). Correlation analysis re-vealed positive bivariate associations between perceived general harm and overuse of medications, and ART adherence (p<0.05); between specific necessity and concerns about ARVs, and perceived general harm and overuse of medications (p<0.05); be-tween HIV adherence self efficacy and ART non-adherence (p<0.05). Multiple regres-sion analysis showed significance for perceived general harm and overuse of medica-tions on ART adherence (F(1;231)=11,583;p<0,001) with perceived general harmful ef-fects and overuse of medications explaining 4.8% of the variance. There was signifi-cance for HIV adherence self-efficacy on ART non-adherence (F(1;41)=4.440; p<0.041), with HIV-ASES explaining 9,8% of the variance. Based on the results, a framework for enhancing ART adherence was developed. Activities in the framework consist of baseline screening for adherence facilitators and barriers using the beliefs about medicine questionnaire and HIV ASES, this is followed by focused interventions on identified barriers of ART adherence
Health Studies
D.Litt. et Phil. (Health Studies)
APA, Harvard, Vancouver, ISO, and other styles
6

Lorenz, Tierney Kyle Ahrold. "Efficacy of an exercise intervention for sexual side effects of antidepressant medications in women." Thesis, 2013. http://hdl.handle.net/2152/26084.

Full text
Abstract:
Antidepressants are associated with sexual side effects (Clayton, Keller, & McGarvey, 2006). Sexual side effects are associated with non-compliance or discontinuance of antidepressants (Werneke, Northey, & Bhugra, 2006). Despite this, there are few empirically supported treatments for antidepressant side effects. However, in laboratory studies, exercise immediately before sexual stimuli improved sexual arousal of women taking antidepressants (Lorenz & Meston, 2012). I evaluated if exercise improves sexual functioning in women experiencing antidepressant-induced sexual side effects. Fifty-two women reporting antidepressant sexual side effects were followed for 3 weeks of sexual activity only. They were randomized to complete either three weeks of exercise immediately before sexual activity (3x/week) or 3 weeks of exercise separate from sexual activity (3x/week). At the end of the first exercise arm, participants crossed to the other. I measured sexual functioning, sexual satisfaction, depression and physical health. Completers showed modest improvements in sexual functioning and satisfaction. For women taking selective serotonin and norepinephrine reuptake inhibitors, exercising immediately before sexual activity was superior to exercise in general. As well as known effects in improved physical and psychological health, exercise may help improve sexual health and pleasure in women taking antidepressants. These findings have important implications for public health, as exercise is accessible, cheap, and does not add to burden of care.
text
APA, Harvard, Vancouver, ISO, and other styles
7

Jhang, Kai-Ming, and 張凱茗. "Explore the efficacy and side effects of common medications in clinical neurology – using national health registry and insurance data." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/gxmw69.

Full text
Abstract:
博士
中山醫學大學
公共衛生學系博士班
106
The present report use National Health Insurance Research Database (NHIRD) to explore the efficacy and side effects of common medications in clinical neurology. There are two main parts in this thesis. First part aimed to elucidate if long-term duration of aspirin and clopidogrel following carotid artery stenting (CAS) would provide an extra clinically relevant benefit. We concluded long-term (more than 42 days as compared with 30-42 days) use of aspirin plus clopidorel after CAS did not decrease the risk of ischemic stroke, composite vascular events or death during 6 months of follow up. The duration (1 month) suggested based on current guidelines is probably suitable. More researches are needed to provide more evidence on the appropriate duration of dual antiplatelet therapy after CAS. Second part investigated the incidence, occurrence time and risk factors of cinnarizine (cz) and flunarizine (fz)-related extrapyramidal side effects (EPSEs). The incidence rates of fz and cz-induced EPSEs were 21.03 and 10.3 per 10,000 person-months, respectively. The hazard ratios (HRs) of EPSEs among fz and cz subjects were 8.03 (95% CI 6.55-9.84) and 3.41 (95% CI 2.50-4.63) when compared with the control individuals. Higher exposure dose and duration, old age, history of essential tremor or cardiovascular disease increased the risk of fz-associated EPSEs. Potential risks should be weighed when considering long-term use of these drugs.
APA, Harvard, Vancouver, ISO, and other styles
8

Huang, Ting-Yu, and 黃亭瑜. "Impact of Tyrosine Kinase Inhibitors and Co-medications on the Efficacy of Patients with Advanced Non-small Cell Lung Cancer." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/39dv28.

Full text
Abstract:
碩士
國立陽明大學
藥理學研究所
106
Tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib and osimertinib are recommended as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-activating mutations. Gefitinib, erlotinib, and afatinib have been reimbursed by the National Health Insurance program for the first-line treatment of patients with stage IIIb or IV NSCLC with EGFR-activating mutations now. However, few studies compared these three TKIs together. Besides, previous studies showed specific medications such as hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), metformin, acid-suppressing (AS) medications, and glucocorticoids might influence efficacy of TKIs. There was few large sample and well-conducted studies to confirm the impact of co-medications. Thus, we conducted a retrospective study using database of Taipei Veterans General Hospital to determine the efficacy of TKIs and impact of co-medications on survival.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "200102 Efficacy of medications"

1

Asadi-Pooya, Ali A., and Michael R. Sperling. Antiseizure Medications. 3rd ed. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197541210.001.0001.

Full text
Abstract:
Abstract The prevalence of epilepsy ranges between 0.6% and 1%, and perhaps 70 million worldwide suffer from this condition. The mainstay of treatment is drug therapy. In the past decade, many new antiseizure medications (ASMs) have been introduced, so that there are now approximately 30 medications available to treat epilepsy. The healthcare provider therefore has many choices. However, having many alternatives also allows for the possibility of choosing an inappropriate or a suboptimal agent. For most seizures, there is little difference in efficacy between the different agents, and other factors chiefly influence drug selection. These include the potential adverse effects, comorbid conditions, concomitant medications, age, and gender, among others. The choice of medication should be guided by knowledge and familiarity with the ASMs. This book is designed as a practical tool for physicians and other healthcare providers. While the authors include a brief formal discussion of the basic pharmacology of each ASM, this text emphasizes how to select and use ASMs in a variety of clinical contexts. The authors discuss choosing drugs when faced with various medical comorbidities; how to correctly prescribe, titrate, and taper drugs; how to monitor drug efficacy and side effects; how to diagnose and manage toxicity; interactions with other drugs; and other relevant issues. The text is designed to fill an unmet need and should lead to improved patient care.
APA, Harvard, Vancouver, ISO, and other styles
2

Castle, David J., Peter F. Buckley, and Fiona P. Gaughran. Effects of antipsychotic medications on physical health. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198811688.003.0006.

Full text
Abstract:
Antipsychotic medications are a crucial part of the core platform upon which effective treatments for schizophrenia are built. While the marketed agents have established efficacy for reduction in the symptoms of schizophrenia, they all carry some side effects. Such effects differ across medications and between individuals. Prescribers need to be aware of the side effect profile of the medications they use, and ensure patients are also aware, so that a true shared decision-making model can be followed in terms of medication choice. Appreciation of long-term risk is required, with treatment choice in the short term having a view to the long term.
APA, Harvard, Vancouver, ISO, and other styles
3

Lynch, Tara A., and J. Christopher Glantz. Seizure Medications Effects on Fetus, Neonate, and Lactation. Edited by Emma Ciafaloni, Cheryl Bushnell, and Loralei L. Thornburg. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190667351.003.0021.

Full text
Abstract:
Medication use in pregnancy requires a careful balance between the risks of fetal teratogenicity and the maternal benefits of disease treatment. For women with epilepsy, there are many antiepileptic medications available for use in pregnancy. Each varies in their safety profile, risk for fetal anomalies, and effectiveness of seizure control. In most scenarios, the benefits of maternal treatment outweigh the risk of fetal effects, especially in cases of refractory epilepsy or severe disease. Many of the newer anti-epileptic drugs appear to have less teratogenic risk than the older medications. The ideal AED is one that is effective from the woman, is least teratogenic, and used at the lowest possible dose. Overall, a detailed understanding of antiepileptic efficacy, the pharmacologic differences in pregnancy, and the potential adverse fetal effects are required for optimal treatment of pregnant patients with epilepsy.
APA, Harvard, Vancouver, ISO, and other styles
4

Mecca, Adam P., and Rajesh R. Tampi. Risk of Death with Atypical Antipsychotic Medications for Dementia. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0016.

Full text
Abstract:
This chapter provides a summary of a landmark meta-analysis that investigated the risks of atypical antipsychotic use to treat psychosis, aggression, or agitation in patients with dementia. The chapter briefly reviews the study design, as well as implications and limitations. A relevant clinical case concludes the chapter. In summary, atypical antipsychotic use for 6 to 26 weeks was associated with increased risk of death (Odds Ratio of 1.54 for antipsychotic vs placebo). There were no differences in risk between individual medications, disease severity, indication for antipsychotic, or treatment setting. In patients with psychosis, agitation, or aggression due to dementia, the efficacy of atypical antipsychotics is questionable and their use comes with considerable risks of side effects and adverse events.
APA, Harvard, Vancouver, ISO, and other styles
5

Yarnell, Eric, Kathy Abascal, and G. M. D. Hooper Carol. Botanical Medicine: Efficacy, Quality Assurance and Regulation. Mary Ann Liebert, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lam, Raymond W. Pharmacotherapy. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199692736.003.0007.

Full text
Abstract:
• The newer antidepressants (SSRIs, SNRIs, other receptor agents) are first-line medications due to improved safety and tolerability over first-generation medications (TCAs, MAOIs).• Selection of an antidepressant must take into account efficacy, depression subtype, safety, side effect profile, simplicity of use, comorbid conditions, concurrent medications, and cost....
APA, Harvard, Vancouver, ISO, and other styles
7

McKay, James R., Henry R. Kranzler, Kyle M. Kampman, Rebecca L. Ashare, and Robert A. Schnoll. Psychopharmacological Treatments for Substance Use Disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0024.

Full text
Abstract:
The treatment of substance use disorders with medications is well established, although most experts agree that pharmacological interventions must be combined with psychosocial therapies. Many type 1 and type 2 controlled trials have shown that the use of nicotine replacement therapy significantly increases abstinence rates. Non-nicotine treatments, such as bupropion and varenicline, have been found in controlled trials to significantly increase abstinence rates. The treatment of alcohol use disorder can be enhanced by three approved medications with different mechanisms of action: disulfiram, naltrexone, and acamprosate. Methadone maintenance treatment has consistently shown efficacy in the treatment of opioid dependence, and buprenorphine has substantially expanded the options for treating the disorder. Although double-blind, placebo-controlled clinical trials of several medications have provided initial evidence of efficacy for cocaine use disorder, efficacy has not yet been shown in multisite trials.
APA, Harvard, Vancouver, ISO, and other styles
8

Guastella, Adam J., Alice Norton, Gail A. Alvares, and Yun Ju Christine Song. Current and Experimental Treatments for Anxiety Disorders. Edited by Dennis S. Charney, Eric J. Nestler, Pamela Sklar, and Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0040.

Full text
Abstract:
There are currently a range of treatments available for anxiety disorders, including pharmacological and behavior-based therapies. The most widely used medications, for which there is considerable evidence of efficacy across a range of anxiety disorders, are the serotonin-selective reuptake inhibitor antidepressants. Benzodiazepines are also widely prescribed and show efficacy for acute anxiety, but their use in the treatment of chronic anxiety syndromes is more problematic. Many patients are not adequately covered by the available range of medications, which is driving interest in potentially new pharmacological approaches. The best established non-pharmacological treatment of anxiety is cognitive behavioral therapy and several related behavioral approaches, which have been shown to be efficacious in a range of anxiety disorders. One of these related approaches is called cognitive bias modification, which aims to alter an individual’s responses to anxiety-provoking stimuli.
APA, Harvard, Vancouver, ISO, and other styles
9

Dittmann, Ralf W., Alexander Häge, Juan D. Pedraza, and Jeffrey H. Newcorn. Non-stimulants in the treatment of ADHD. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198739258.003.0042.

Full text
Abstract:
The psychostimulants methylphenidate and amphetamine are the most effective and frequently prescribed medications for ADHD. But these agents also have certain limitations; for example, they are controlled substances, and a proportion of patients do not achieve optimal symptom response, or they do not tolerate treatment well. There are two classes of regulatory-approved non-stimulant medications for ADHD, the selective norepinephrine reuptake inhibitors (atomoxetine) and the long-acting alpha-2 adrenergic agonists (guanfacine and clonidine). In addition, several other medication classes have been used off-line with reported efficacy, while others are in clinical development. While the non-stimulant medications are, on average, not as effective as the psychostimulants, they can be very helpful in treating certain patients with ADHD (and respective comorbidities)—either as monotherapy or as adjunctive agents. This chapter reviews a selection of current non-stimulant medications that are clinically used or studied for ADHD.
APA, Harvard, Vancouver, ISO, and other styles
10

Nasrallah, Henry A., and Priyanka Sarihan. The Use of Antipsychotics in PTSD. Edited by Charles B. Nemeroff and Charles R. Marmar. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190259440.003.0036.

Full text
Abstract:
Psychosis is one of the manifestations of the post-traumatic stress Disorder (PTSD) syndrome. Several controlled and uncontrolled trials have been published about the efficacy and safety of second-generation antipsychotic drugs in PTSD. In this chapter, we review the various studies and provide data related to the management of psychotic symptoms in the context of PTSD. Most second-generation antipsychotic agents exert efficacy in PTSD, with varying degrees of tolerability and safety. In many cases, they may be used in combination with other medications targeting depression and anxiety, the most common symptom clusters in PTSD.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "200102 Efficacy of medications"

1

Deacon, Brett J., and Glen I. Spielmans. "Is the Efficacy of “Antidepressant” Medications Overrated?" In Psychological Science Under Scrutiny, 250–70. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2017. http://dx.doi.org/10.1002/9781119095910.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gauthier, Serge, Howard Feldman, and Erich Mohr. "Minimal Efficacy Criteria for Medications in Alzheimer Disease." In Alzheimer Disease, 431–35. Boston, MA: Birkhäuser Boston, 1994. http://dx.doi.org/10.1007/978-1-4615-8149-9_71.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dunlop, Boadie Waid, and Carolina Medeiros Da Frota Ribeiro. "Randomized Controlled Trials and the Efficacy of Psychotropic Medications." In NeuroPsychopharmacotherapy, 1–56. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-56015-1_4-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dunlop, Boadie Waid, and Carolina Medeiros Da Frota Ribeiro. "Randomized Controlled Trials and the Efficacy of Psychotropic Medications." In NeuroPsychopharmacotherapy, 305–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-62059-2_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Denenberg, Sagi. "Psychopharmacology." In Small animal veterinary psychiatry, 142–68. Wallingford: CABI, 2021. http://dx.doi.org/10.1079/9781786394552.0142.

Full text
Abstract:
Abstract This chapter presents the use and efficacy of some of the most commonly used medications and several less commonly used medications to treat psychiatric conditions and abnormal behaviours of cats and dogs.
APA, Harvard, Vancouver, ISO, and other styles
6

Denenberg, Sagi. "Psychopharmacology." In Small animal veterinary psychiatry, 142–68. Wallingford: CABI, 2021. http://dx.doi.org/10.1079/9781786394552.0009.

Full text
Abstract:
Abstract This chapter presents the use and efficacy of some of the most commonly used medications and several less commonly used medications to treat psychiatric conditions and abnormal behaviours of cats and dogs.
APA, Harvard, Vancouver, ISO, and other styles
7

Lehmann, Susan W. "Mood Stabilizers." In Psychiatric Aspects of Neurologic Diseases. Oxford University Press, 2008. http://dx.doi.org/10.1093/oso/9780195309430.003.0026.

Full text
Abstract:
The term ‘‘mood stabilizers’’ refers to a heterogeneous group of medications that are effective in the treatment of bipolar disorder, an illness characterized by recurrent episodes of mania and major depression. The list of mood stabilizers includes lithium, several anticonvulsant medications, and atypical antipsychotic medications. For some of these medications, there have been randomized, placebo-controlled studies demonstrating efficacy in reducing the severity and frequency of illness episodes (Kahn et al., 2000). For other medications, the evidence supporting therapeutic use in mood disorders is more anecdotal or preliminary. Late-onset bipolar disorder beginning after 50 years of age is more likely to be associated with comorbid medical or neurologic condition, or their treatments (McDonald, 2000; Depp and Jeste, 2004). A number of medications have been known to precipitate manic episodes. These include antiparkinsonian medications, corticosteroids, anticholinergic agents, and antidepressants. In addition, manic episodes may develop in patients with Huntington’s disease, multiple sclerosis, brain tumors, seizure disorders, dementia, neurosyphilis, human immunodeficiency virus (HIV), and some poststroke syndromes. The goal of long-term psychiatric management is to minimize affective upheaval and to diminish frequency of mood cycling. Psychotic symptoms are common in bipolar disorder, and severe behavioral disturbances such as physical aggression can occur as well during manic episodes. Depressive episodes are accompanied by a risk of suicide. Given the potential for these severe complications, and the need for continual medication reassessment and adjustment, the long-term pharmacologic and psychologic treatment of bipolar disorder is best managed by a psychiatrist. Lithium, the oldest of the mood-stabilizing medications, is also considered to be the ‘‘gold standard’’ of treatment against which all other potentially mood-stabilizing medications are compared. It is still the treatment of choice for many patients with bipolar disorder, and it has been approved by the U.S. Food and Drug Administration for treatment of manic episodes and for maintenance therapy. At least eight placebo-controlled, randomized trials have shown lithium to have efficacy in maintenance treatment of bipolar disorder (Goodwin, 2002). Lithium is effective in reducing risk of recurrent episodes of both mania and depression, although studies have suggested greater superiority in reducing risk of manic episodes.
APA, Harvard, Vancouver, ISO, and other styles
8

Asadi-Pooya, Ali A., and Michael R. Sperling. "Choices of Antiseizure Medications Based on Specific Epilepsy Syndromes and Seizure Types." In Antiseizure Medications, 119–30. 3rd ed. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197541210.003.0005.

Full text
Abstract:
Abstract Variables that affect the suitability of a specific antiseizure medication (ASM) for patients with epilepsy include ASM-specific variables, patient-specific variables, and nation-specific variables. For many patients, several agents are good choices. However, for the generalized epilepsies, valproate may have the greatest efficacy, while in focal epilepsies many drugs are potentially good choices.
APA, Harvard, Vancouver, ISO, and other styles
9

Tsze, Daniel S., and Jason Reynolds. "Intranasal Medications." In The Pediatric Procedural Sedation Handbook, edited by Cheryl K. Gooden, Lia H. Lowrie, and Benjamin F. Jackson, 322–28. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190659110.003.0050.

Full text
Abstract:
The intranasal route is an effective means of administering sedatives and analgesics. It is a needle-free alternative to intravenous or intramuscular routes, it is not subject to first-pass metabolism, and its efficacy approaches that of intravenous administration. There is absorption through the highly vascular nasal mucosa, as well as utilization of the nose–brain pathway that bypasses systemic circulation and the blood–brain barrier and transports medications directly to the brain. Intranasal administration of sedative and analgesic medications has been shown to be safe and effective for children in a variety of settings. It provides an opportunity to avoid intravenous line placement in many situations, which may reduce the pain and anxiety associated with many diagnostic and therapeutic procedures in children. More studies are needed to compare important sedation outcomes between intranasal sedation regimens and the more common intravenous sedation regimens in order to guide best practice.
APA, Harvard, Vancouver, ISO, and other styles
10

Konstas, Anastasios G. P., Andreas Katsanos, Luciano Quaranta, Dimitrios G. Mikropoulos, Paris G. Tranos, and Miguel A. Teus. "Twenty-four hour efficacy of glaucoma medications." In Progress in Brain Research, 297–318. Elsevier, 2015. http://dx.doi.org/10.1016/bs.pbr.2015.06.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "200102 Efficacy of medications"

1

Kreuter, Michael, Jin Woo Song, John T. Huggins, Benoit Wallaert, Wibke Stansen, Manuel Quaresma, and Bruno Crestani. "Concomitant medications and efficacy of nintedanib in patients with IPF." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4891.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gómez-Carreño, Carlos Rodríguez, Antonio Ramírez García, Luis Beato Fernández, Irene Díaz Quero, and Estefanía Segura Escobar. "Craving and Priming of alcohol in depressive disorders. Bibliographic review and new therapies." In 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020p140.

Full text
Abstract:
Acute alcohol consumption produces positive reinforcement effects, through activation of brain reward circuit, includes limbic system structures (accumbens system and hippocampus). The comorbidity of depressive episode and alcohol abuse makes it necessary to propose new strategies for the treatment of this frequent clinical situation. We conducted a literature review of the combined treatments for major depressive disorder (MDD) with alcohol abuse. We review current literature on the use of new treatments in alcohol consumption with pattern of abuse (binge drinking). Recent studies support the potential clinical importance of NMDA receptor antagonism among the mechanisms underlying the subjective effects of ethanol in humans. The efficacy of medications for alcohol dependence remains modest, and there are no strong clinical predictors of treatment response. We analyze approved medications used today: Acamprosate (NMDA modulator), disulfiram (acetaldehyde dehydrogenase inhibitor), naltrexone (opioid antagonist), nalmefene (opioid antagonist). Promising current studies suggest the glutamatergic pathway and medications such as ketamine could have a hopeful future in the treatment of alcohol use disorder associated with affective disorders.
APA, Harvard, Vancouver, ISO, and other styles
3

Hinrichsen, H., A. Stoehr, M. Cornberg, H. Klinker, R. Heyne, C. John, KG Simon, et al. "Real-world efficacy of EBR/GZR in HCV GT1 patients with multiple comorbidities and medications: results from the DHC-R." In 36. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3402277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Park, CH, EH Kim, and SW Park. "COMPARATIVE EFFICACY OF VARIOUS ANTI-ULCER MEDICATIONS FOR ULCER HEALING AFTER GASTRIC SUBMUCOSAL DISSECTION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS." In ESGE Days 2018 accepted abstracts. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1637057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Virgínio, Maria Eduarda Cunha, Lara Hessmann Gonzalez, Rafael Rodrigues Pinheiro dos Santos, Ana Carla Mondek Rampazzo, Gabrielli Algazal Marin, Mariana Ramos do Nascimento, Igor Ruan de Araújo Caetano, Maria Letícia Nogueira, José Ângelo Favoreto Guarnieri, and Carlos Alexandre Martins Zicarelli. "The use of Amantadine in Cognitive and Behavioral Recovery After Severe Cranioencephalic Trauma: A Systematic Review." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.572.

Full text
Abstract:
Background: Traumatic brain injury (TBI) is the main cause of death among individuals between 1 and 44 years of age, and severe TBI is associated with a mortality rate between 30% and 70%. In this context, randomized clinical trials have studied medications to reduce morbidity in severe TBI, one of which is Amantadine. This drug acts on the increase of extracellular dopamine and as an NMDA antagonist. Objectives: Developing a systematic review of systematic reviews to evaluate the efficacy of Amantadine in reducing morbidity in patients with severe TBI. Methodology: The search was conducted in the PubMed, Embase, Cochrane Library, and Portal Regional BVS databases. Results: Eleven systematic reviews were included. The literature review of 7 articles demonstrated the efficacy of treatment with Amantadine in the following clinical aspects after TBI: aggression, irritability, agitation, mood, and attention deficit. On the other hand, one article did not consider the use of Amantadine significantly beneficial, due to increased agitation in critically ill patients, suggesting that there is worsening of the condition in individuals with cognitive, executive, memory, and attention symptoms. Therefore, three studies reported that there was not enough evidence for the use of this drug in patients with severe TBI. Conclusions: The results are heterogeneous. However, this study found good efficacy of Amantadine for cases of agitation/aggression in severe TBI and in cases of diffuse axonal lesion that compromises the glutamate pathways.
APA, Harvard, Vancouver, ISO, and other styles
6

Araújo, Catarina Secundino Tavares de, Maria Clara Coppieters Gusmão, and Rodrigo Mesquita Costa Braga. "Cannabidiol Use as Treatment for Refractory Epilepsies." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.568.

Full text
Abstract:
Introduction: Refractory epilepsies have a great impact in patients’ quality of life. Thus, studies with alternative drugs are extremely important to seek for effective treatments to control the condition, and cannabidiol (CBD) has shown promising results. Objectives: To analyze CBD’s efficacy as an alternative treatment of patients with refractory epilepsy. Design and setting: this study is a literature review from Universidade Federal da Bahia. Methods: We searched the following formula on PubMed: [cannabidiol] AND [epilepsy]. The inclusion criteria were clinical trials published from 2016-2021. Results: 25 articles were found, from which 18 were selected and, from those, 1092 patients were analyzed. All studies pointed to a reduction in frequency and/or intensity of epileptic crisis in adults and children with refractory epilepsy using CBD, independently of the etiology. In Laux’s study, they noted reductions of 50% and 44% in motor and total seizures (respectively). Moreover, Birnbaum’s study showed that using CBD with a meal may cause variability of exposure of patients to the drug. Adverse effects were dose dependent, mainly diarrhea, sleepiness and less appetite. The interaction between CBD and anticonvulsants was not shown to have a prejudicial or neutralizing effect. Conclusion: CBD was shown to be capable of attenuating attacks in patients with refractory epilepsy. However, more randomized clinical trials are needed to analyze the efficacy and the safety of these medications in the short and long term.
APA, Harvard, Vancouver, ISO, and other styles
7

Six, A. J., J. W. Louwerenburg, R. Braams, W. L. Mosterd, A. C. Bredero, H. J. Kerkkamp, E. J. P. Brommer, and N. M. van Hemel. "EARLY RESULTS OF A RANDOMIZED, DOUBLE-BLIND DOSE-RANGING STUDY OF I.V. STREPTOKINASE FOR ACUTE MYOCARDIAL INFARCTION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642991.

Full text
Abstract:
101 patients suffering from acute myocardial infarction during less than 4 hours were immediately treated with intravenous (i.v.) streptokinase (SK), infused in 1 hour. No concomitant medications like steroids, salicylates or anti-arrhythmic drugs were routinely given.Patients were blindly allocated to one of four dosages of SK (see below). Coronary angiography was performed within 3 hours after SK infusion in 90% of all patients . The infarct-related vessel was open in 59% of 91 patients. The results in the four dosage groups were as follows:Haematomas at the puncture site were common complications in all groups. No strokes occurred, nor life-threatening bleeding complications. Blood transfusion was needed in only one parient, who had an important bleeding and formation of a large haematoma at the puncture site.It is concluded that there is a trend to better results of higher doses of i.v. SK in patients suffering from acute myocardial infarction without an evident rise of the rate of complications. The efficacy and safety of recently developed fibrinolytic drugs and streptokinase should be compared at optimal dosages.
APA, Harvard, Vancouver, ISO, and other styles
8

Aharonson, Vered, Ilana Schlesinger, Andre McDonald, Steven Dubowsky, and Amos Korczyn. "Monitoring of Parkinson’s Patients Gait Using Simple Walker Based Motion Sensing and Data Analysis." In 2017 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/dmd2017-3301.

Full text
Abstract:
Parkinson’s disease (PD) is a degenerative disease with diverse clinical features. At present, there is no definitive test for the diagnosis of PD [1]. Instead, PD is diagnosed using clinical criteria which are based on the presence and presentation of signs such as rest tremor, bradykinesia, rigidity, loss of postural reflexes, shuffling gait and freezing, as well as non-motor symptoms. Various treatments, ranging from physical therapy and medications to invasive treatments, can help relieve some PD symptoms. These treatments need quantitative monitoring and efficacy evaluation methods in order to provide higher quality, patient-centered care. A quantitative assessment of the patients’ clinical symptoms can also provide a timely alert to adverse events [2]. A variety of devices employing sensors with the purpose of monitoring PD patients’ symptoms were developed [3, 4]. Most of these devices are costly and / or complex in operation and maintenance, which limits their practicality in busy hospital / clinic environments and for home use. Moreover, they do not provide appropriate solutions for monitoring more severe cases of PD, where the patient requires a walking aid such as a cane or walker.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "200102 Efficacy of medications"

1

Dai, Hengheng, Haisong Li, Bin Wang, Jisheng Wang, Jingjing Zhang, Ying Chen, Xuecheng Zhang, et al. Evaluation of the efficacy of medications for heart failure: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lu, Qi, Haili Wang, Weizheng Wang, Yu Gao, Xuefeng Li, Ying Wang, Weiwan Yang, and Hongfeng Wang. Efficacy of Electroacupuncture in Painful Diabetic Peripheral Neuropathy: A protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0040.

Full text
Abstract:
Review question / Objective: The aim of this study is to perform a meta-analysis to evaluate the effectiveness of electroacupuncture in the treatment of painful diabetic peripheral neuropathy (PDNP).And to provide data support for electroacupuncture as an effective means to treat pain of nervous system diseases. Condition being studied: Diabetes mellitus (DM) affects more than six hundred million population worldwide till 2045. The most common form is chronic, distal, and symmetric sensorimotor polyneuropathy, while other uncommon forms include asymmetric or focal neuropathy, such as diabetic muscle atrophy, trunk radiculopathy, and compression palsy. About 11.4% and 40.5% of patients have severe and moderate pain respectively. Currently, symptomatic treatment of PDPN is based on the application of medications that target the symptoms of PDPN. However, the clinical efficacy of PDPN patients varies greatly from individual to individual.Traditional Chinese medicine electroacupuncture have shown its unique advantages in the treatment of PDPN. Although its mechanism is complex and unclear, it can still be used in the clinical treatment of PDPN for a long time. We therefore present a systematic review of the benefits of electroacupuncture in improving PDPN by including the as many as possible randomized controlled trials.
APA, Harvard, Vancouver, ISO, and other styles
3

Kwak, Sang Gyu, Yoo Jin Choo, Soyoung Kwak, and Min Cheol Chang. Efficacy of Transforaminal, Interlaminar, and Caudal Epidural Injections in Lumbosacral Disc Herniation: A Systematic Review and Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0091.

Full text
Abstract:
Review question / Objective: Epidural injection (EI) has been used to manage lower back or radicular leg pain from herniation of lumbar disc (HLD). Three types of EI techniques, including transforaminal (TFEI) interlaminar (ILEI), and caudal epidural injections (CEI), are being applied. We aimed to evaluate the comparative effect of TFESI, ILEI, and CEI for reducing pain or improving function in patients with HLD. Condition being studied: For controlling inflammation by the HLD, various oral medications and procedures are used. Among these therapeutic methods, EI of the drugs is frequently used in clinical practice. Its positive HLD-induced pain reducing effect was reported in several previous studies. Three types of techniques, including TFEI, ILEI, and CEI, have been utilized in clinical practice. conflicting outcomes as to which technique is superior were reported in previous studies. So far, some meta-analysis studies for comparing the effects of different EI techniques on HLD were conducted. However, these previous studies conducted comparison between two procedures among TFEI, ILEI, and CEI. In the current study, using network meta-analysis, we synthesize and compare the effects of TFEI, ILEI, and CEI on pain from HLD, together.
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Xin. The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0075.

Full text
Abstract:
Review question / Objective: The objectives of this systematic review were to evaluate the efficacy and safety of the three existing anti-CD20 antibodies for the treatment of relapsing multiple sclerosis and to aid clinicians in choosing medications. Eligibility criteria: We set the inclusion criteria as follows: (1) study type: RCT; (2) language restriction: only available in English; (3) participants: patients ≥18 years of age diagnosed with relapsing MS, whether with a relapsing–remitting course or a secondary progressive course; (4) intervention: anti-CD20 antibody treatments including ocrelizumab, ofatumumab, rituximab, and corresponding control including placebo and active treatments; (5) outcomes: clinical outcomes including annualized rate of relapse (ARR), the number of patients free of relapse, and the number of patients with confirmed disease progression (CDP); magnetic resonance imaging(MRI) outcomes including gadolinium-enhancing lesion change in T1, change in the volume of lesions on T2, the number of patients with no new or newly enlarged lesions in T2 and the brain volume change (BVC); safety outcomes including adverse events (AEs) and serious adverse events (SAEs). Included RCTs were not requested to supply all the outcomes mentioned above. We set the exclusion criteria as follows: (1) study type: retrospective studies, cohort studies, case reviews and case reports; (2) patients diagnosed with primary progressive MS.
APA, Harvard, Vancouver, ISO, and other styles
5

Pu, Fenglan, Tianli Li, Yingqiao Wang, Chunmei Tang, Chen Shen, and Jianping Liu. Cordyceps preparations for preventing contrast-induced nephropathy: A protocol of systematic review of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0098.

Full text
Abstract:
Review question / Objective: To systematically evaluate the efficacy and safety of cordyceps preparations as a complementary preventive therapy for Contrast-induced nephropathy (CIN). Condition being studied: At present, contrast agents are widely used in diagnostic and interventional radiology examinations worldwide. However, they can affect kidney function and cause a risk of renal impairment. Contrast-induced nephropathy (CIN) is defined as a rise in serum creatinine (SCr) levels by ≥ 25% of baseline or 44 µmol/l from the pre-contrast value within 72 h of intravascular administration of a contrast agent in the absence of an alternative etiology. The incidence of CIN varies widely among studies depending on study population and baseline risk factors, as for high-risk groups such as pre-existing renal insufficiency, diabetes, advanced age, or receiving nephrotoxic agents, the incidence is up to 30–50%. To date, CIN has been the third most common cause of hospital-acquired renal failure, after impaired renal perfusion and nephrotoxic medications, which can lead to longer hospital stay, increased costs and higher mortality.
APA, Harvard, Vancouver, ISO, and other styles
6

Cerón, Lissette, Mishelle Pacheco, Bolivar Delgado, and Wilson Bravo. Therapies for bruxism in dentistry: A systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0080.

Full text
Abstract:
Review question / Objective: The aim of this study is to evaluate the methodological quality of the literature and the risk of bias used in systematic reviews of therapies for bruxism in dentistry, applying the Amstar II qualitative guide and to answer the following question: What do we know so far about the different treatments applied for bruxism and their effectiveness, as well as what is the overall confidence of the systematic reviews evaluating this topic? Condition being studied: There is an ongoing debate about the causal factors associated with patients diagnosed with bruxism and thus various treatment approaches, so according to the available scientific evidence there is no consensus on which is the most effective. (4) (8) (10). According to several studies, occlusal splints do not currently have a scientifically proven efficacy for the management of bruxism, because they lack randomized controlled clinical studies, and should therefore be considered as a limited treatment modality, since the effect of the splints does not seem to address the cause of bruxism and serves mainly for the management of the signs and symptoms of this disorder (11) (12). Alternative therapies such as relaxation and biofeedback have been proposed for bruxism, especially in cases of daytime bruxism, which are more related to stress and anxiety. (13). There are also studies that support the use of the NTI-tssa device can be used successfully, however, it may present side effects if necessary checks and readjustments are not performed (14). Some medications can be used to decrease bruxing episodes, but some pharmacological treatments may not be safe if used for prolonged periods of time, considering the inherent side effects or risks of dependence (15).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '200102 Efficacy of medications' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography